Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JCASTRE-Zero enzalutamide study in non-metastatic castration-resistant prostate cancer
jRCTs061180030Completed
- Sponsor
- Astellas Pharma
- Start
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of enzalutamide in prostate cancer (PCa), sponsored by Astellas Pharma. Primary endpoint: PSA progression-free survival. Started Jan 2016; status: completed.
02
Drugs
enzalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on jRCTs061180030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs061180030.